Gut-Blood Barrier and Enzyme Delivery Routes

The gut epithelium separates two different uricase hypotheses: degrade urate in the lumen without systemic enzyme exposure, or move an active enzyme or encoded payload across the barrier. Evidence for one route does not validate the other.

Luminal UOX hypothesis

The luminal hypothesis exploits urate already secreted into the intestine. It does not require intact UOX to enter the bloodstream. Human oral-enzyme studies support the general proposition that an active luminal enzyme can alter systemic urate handling, but they do not validate an engineered yeast or koji construct, a delivery format, or a dose. Clinical Trial evidence for the modality; Mechanistic Extrapolation for an untested engineered construct. See gut-lumen sink and uricase.

An engineered UOX candidate therefore remains conditional on two preclinical gates:

1. Build and characterize exact candidate configurations in their intended host or material, then use validation §1.33 to identify whether any produces product at the terminal-ileal clinical-cohort substrate prior without an unacceptable peroxide or viability signal.
2. A surviving topology must pass validation §1.36, which tests the coupled loss of urate antioxidant capacity and UOX-derived hydrogen peroxide before animal escalation.

Until those gates pass, no fermented preparation, live organism, lysate, powder, or capsule is an established delivery format.

Barrier-crossing hypotheses

Blood-barrier exploits catalogs paracellular, transcellular, vesicular, mucosal, and barrier-bypassing routes. These are separate delivery programs because systemic or tissue exposure introduces route-specific pharmacokinetic, immunogenicity, and safety questions. A route should be advanced only when the target requires exposure outside the lumen and the proposed carrier has a direct measurement and falsification plan.

For UOX, systemic and intra-articular routes should be compared with existing systemic uricase evidence rather than inferred from luminal feasibility. Deliberately increasing epithelial permeability also requires direct barrier-integrity and translocation measurements; theoretical bioavailability is not a safety result.

Immune boundary

Mucosal immune tolerance is a biological phenomenon, not a guarantee for a recombinant enzyme or engineered organism. The immune result depends on the antigen, formulation, exposure pattern, barrier state, host, and whether material reaches systemic compartments. Tolerability observed for one oral-enzyme formulation cannot be transferred to engineered yeast, engineered koji, or another payload. Each candidate needs direct local and systemic immune readouts in its own delivery configuration.

Decision rule

• Use a luminal route only if activity at physiological substrate, peroxide control, viability, and the §1.36 safety interaction survive testing.
• Pursue barrier crossing only when a gout-relevant target cannot be reached from the lumen and the route has a measurable exposure advantage.
• Kill or redirect the construct when the required compartment cannot be reached with an acceptable safety margin.

This page concerns delivery logic. Chassis selection and cross-track ranking belong in the modality–chokepoint matrix.